Viatris agrees to buy Pacira and Viatris stock falls 3.07 percent
Published on 10/08/2026 at 18:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Viatris agreed on October 8, 2026 to acquire Pacira for USD 1.65 billion, or USD 36.50 per share in cash.
- Second-quarter 2026 revenue reached USD 3.76 billion, up 4.90 percent year over year, while operating profit was USD 6.30 million.
- Viatris stock was at EUR 15.14 at Lang & Schwarz on October 8, 2026, down 3.07 percent versus the EUR 15.62 prior close.
Viatris stock (ISIN US92556V1061) was trading at EUR 15.14 at Lang & Schwarz on October 8, 2026 at 6:39 p.m. CEST, down 3.07 percent versus the EUR 15.62 prior close. The company agreed to acquire Pacira BioSciences for USD 36.50 per share in cash, valuing the transaction at USD 1.65 billion, as BioSpace reported on October 8, 2026.
Viatris events carry three figures
On August 6, 2026, Viatris reported second-quarter revenue of USD 3.76 billion, up 4.90 percent from USD 3.58 billion a year earlier, according to VantagePoint. The same source reported adjusted earnings per share of USD 0.69, up from USD 0.62.
On September 8, 2026, Argus raised its Viatris price target to USD 20 from USD 15, according to VantagePoint. The October 8 Pacira agreement is the latest event and adds a specialty-medicine platform to Viatris' established generic and branded portfolio.
What does the deal add?
Pacira generated USD 746.00 million in revenue and USD 177.00 million in adjusted EBITDA during the twelve months ended June 30, 2026, according to BioSpace. The products are EXPAREL and ZILRETTA, two marketed non-opioid pain medicines that Viatris expects to distribute through its international infrastructure.
The transaction is expected to close by the end of 2026 and is described as immediately accretive to Viatris' financial guidance metrics. Viatris said it expects to fund the purchase mainly with excess cash and the remainder with short-term borrowings, while describing the effect on gross leverage as minimal, according to BioSpace.
Next results arrive November 5
Viatris is scheduled to report third-quarter 2026 results on November 5, 2026, with the conference call set for 8:30 a.m. ET, according to BioSpace. The report will provide the first scheduled update after the Pacira announcement and will show whether the acquisition changes the company's operating priorities before closing.
Stock trades below its US session quote
Viatris had a market capitalization of USD 19.7 billion and a 52-week range of USD 9.69 to USD 18.43 as of October 8, 2026. Its Nasdaq quote was USD 16.93 on October 8, 2026 at 12:48 p.m. ET, separate from the euro reference price.
At Lang & Schwarz, Viatris was trading at EUR 15.14 on October 8, 2026 at 6:39 p.m. CEST, down 3.07 percent versus the EUR 15.62 prior close. The further course of trading is shown by the continuously updated real-time quote of Viatris stock.
Viatris stock at a glance
- Company: Viatris Inc.
- ISIN: US92556V1061
- Ticker: VTRS
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 8, 2026, 6:39 p.m. CEST): EUR 15.14
- Change versus prior close: minus 3.07 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 15.62
- Market capitalization: USD 19.7 billion (as of October 8, 2026)
- 52-week range: USD 9.69-18.43 (as of October 8, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 5, 2026
Market context: Market report Nasdaq Composite.
